← All Myriad Genetics INC filings

Myriad Genetics INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
MYGN
Myriad Genetics INC
DEF: Myriad Genetics Sets 2026 Annual Meeting Date, Proposes Director Elections
Myriad Genetics, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, to elect directors, ratify auditor selection, and approve executive compensation and equity plans.
NASDAQ
MYGN
Myriad Genetics INC
DEFA14A: Myriad Genetics Files Definitive Proxy Statement with SEC
Myriad Genetics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
MYGN
Myriad Genetics INC
DEF: Myriad Genetics Announces Leadership Transition and Highlights 2024 Achievements in Proxy Statement
Myriad Genetics' proxy statement reveals a leadership transition with Sam Raha succeeding Paul Diaz as CEO, alongside strong 2024 financial performance and strategic advancements.
NASDAQ
MYGN
Myriad Genetics INC
DEFA14A: Myriad Genetics, Inc. Files Definitive Proxy Statement with SEC
Myriad Genetics has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.
NASDAQ
MYGN
Myriad Genetics INC
DEF 14A: Myriad Genetics Reports Strong 2023 Results, Focuses on Strategic Growth
Myriad Genetics highlights 11% revenue growth in 2023 and strategic advancements in molecular diagnostics and precision medicine.